In vitro mass multiplication of Jatropha (Jatropha curcas L.) through axillary bud culture

The present investigation was conducted for mass multiplication of Jatropha curcas L. through axillary bud culture. For this nodal segment from 3-5 months old nursery grown plants were used as explants for axillary bud culture. The sterilization treatment involving dipping explants in 0.1 per cent HgCl2 solution for 5 minutes resulted in minimum contamination and maximum establishment of nodal explants. The treatment MS medium supplemented with 1.0 mg/L BAP and 1.0 mg/L IAA was the best for culture establishment, shoot proliferation and multiplication of the axillary buds which exhibited highest value in each parameter like establishment (76.1%), number of days taken for shoot initiation (3.1 days), length of longest shoot (6.8 cm), number of leaves on main shoot (7.1) and number of shoots per explant (6.3). Among different treatments for root initiation, half MS media fortified with 1 mg/L IBA, 3 mg/ L NAA and 0.25 g AC gave best result in maximum number of rooting percentage (60) with minimum time taken for root initiation (13.3 days), produced maximum number of roots per shoots (5.1) and length of longest root (4.9 cm) when established shoots were treated with it. Such produced plantlets showed nearly cent per cent survival after hardening and acclimatization. It showed that explants surface sterilized with 0.1 per cent HgCl2 solution for 5 minutes inoculated in MS medium supplemented with 1.0 mg/L BAP and 1.0 mg/L IAA and half MS media fortified with 1 mg/L IBA, 3 mg/L NAA and 0.25 g AC were best in shoot establishment and root development respectively for mass multiplication of J. curcas L. through axillary bud culture

EFFECT OF ANTI DIABETIC POWDER (FENUGREEK LEAVES + BITTER GOURD) AND GREEN TEA ON BLOOD SUGAR STATUS OF DIABETIC PATIENT

Abstract: Diabetes mellitus, often simply referred to as diabetes -is a group of metabolic disease in which a person has high blood sugar, because the body does not produce enough insulin. The present study was planned to perform in three parts to fulfill the objectives that is prevalence rate of type-2 diabetes mellitus in middle age group, Vadodara. Product preparation, supplementation, Bio-clinical assessment before and after supplementation to know it's effectiveness on glucose present in the body and effect of pancreas to produce insulin in proper amount. Study indicated that most of the middle age persons have high blood glucose level. When they were supplemented with diabetic powder (fenugreek leaves + bitter gourd) and Green Tea i.e. for 30 days, their blood glucose level was reduced, demonstrating positive effect in middle age group. We can conclude that for prevention of type-2 diabetes mellitus it is very essential to modify the meal pattern and increase the physical activity

Machine Learning Approach for Carbon Capture and Utilization – a Prelimenary Investigation

Due to the increase in the industrialization the environment is deteriorating. The major concern is to identify the sources those are contributing to the environment change. One of the major sources of interest is carbon in this domain. The carbon capture has been carried out with different methods and data is analyzed. The process of performing real time experiments is time consuming and sometimes the accurate results may not be obtained. In order to overcome the issues mentioned, a combined approach with machine learning is presented by the authors in this article. The present work provides a detailed overview of the laboratory processes for Carbon Capture and Utilization (CCU). In addition to this a detailed investigation of machine learning along with its probable implementation is presented. The combined approach will be beneficial as it efficient, quick and safe. The proposed approach will be beneficial to the industries as well as environment

Clonal evaluation for early growth performance of Eucalyptus in South Gujarat, India

This study was carried out in College of Forestry, Navsari Agricultural University, Navsari, Gujarat. Total 20 clones having age of 5 ½ years were selected for early growth evaluation at field condition. There was a significant variation (P < 0.05) among 20 clones of Eucalyptus for growth parameters viz., tree height, DBH, mid-diameter, form quotient and volume of standing tree. Tree height varied from 18.5 to 23.6 m with DBH range of 11.47 to 16.07 cm. Mid-diameter indirectly helps to assess the tapering of tree and it ranged from 6.99 to 10.57 cm among 20 clones. The form quotient was used while calculation of volume of Eucalyptus clones. The form quotient varied between 0.58 and 0.71 with overall mean of 0.63 at studied site. Volume of standing tree ranged from 0.12 to 0.28 m3. The overall results showed that clones such as C12 (P2045), C17 (B2253), C4 (P413), C8 (P526), C7 (P498), C16 (SRO16) and C11 (P3020) performed superior for early growth attribute and stem form and these clones suggested for large scale plantation in South Gujarat region

Syntheses, spectral characterization and antidiabetic activities of oxidovanadium(V) complexes with bi-and tridentate ligands

254-262Four new oxidovanadium(V) complexes [VO(L1)(Mol)] (1), [VO(L2)(Mol)] (2), [VO(L3)(Mol)] (3) and [VO(L4)(Mol)] (4)(where L1-L4 = aroylhydrazones and Mol = maltol) have been synthesized with different ligands. The complexes havebeen characterized using microanalysis, spectral fab mass, UV-visible, electrochemical (cyclic voltammetry and differentialpulse voltammetry), density functional theory calculations have been performed to predict the optimized geometry, globalreactivity parameters and electron density. In these complexes, the d-d absorption band is not observed as being d0 vanadiumcentres in these complexes. The electrochemical behaviour of these complexes are explored by cyclic voltammetry anddifferential pulse voltammetry (DPV). All complexes exhibit one electron transfer i.e., reduction of vanadium(V) tovanadium(IV). These complexes are screened for in vitro α-glucosidase and α-amylase inhibition study. Complex 3 has aninteresting insulin-like activity

Using system dynamics modelling to assess the economic efficiency of innovations in the public sector - a systematic review

Background Decision-makers for public policy are increasingly utilising systems approaches such as system dynamics (SD) modelling, which test alternative interventions or policies for their potential impact while accounting for complexity. These approaches, however, have not consistently included an economic efficiency analysis dimension. This systematic review aims to examine how, and in what ways, system dynamics modelling approaches incorporate economic efficiency analyses to inform decision-making on innovations (improvements in products, services, or processes) in the public sector, with a particular interest in health. Methods and findings Relevant studies (n = 29) were identified through a systematic search and screening of four electronic databases and backward citation search, and analysed for key characteristics and themes related to the analytical methods applied. Economic efficiency analysis approaches within SD broadly fell into two categories: as embedded sub-models or as cost calculations based on the outputs of the SD model. Embdedded sub-models within a dynamic SD framework can reveal a clear allocation of costs and benefits to periods of time, whereas cost calculations based on the SD model outputs can be useful for high-level resource allocation decisions. Conclusions This systematic review reveals that SD modelling is not currently used to its full potential to evaluate the technical or allocative efficiency of public sector innovations, particularly in health. The limited reporting on the experience or methodological challenges of applying allocated efficiency analyses with SD, particularly with dynamic embedded models, hampers common learning lessons to draw from and build on. Further application and comprehensive reporting of this approach would be welcome to develop the methodology further

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life. rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25 mcg kg−1wk−1) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose–response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg−1wk−1cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl−1respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing. © 2001 Cance Cancer Research Campaig

Establishing a clinical phenotype for cachexia in end stage kidney disease - study protocol.

BACKGROUND: Surveys using traditional measures of nutritional status indicate that muscle wasting is common among persons with end-stage kidney disease (ESKD). Up to 75% of adults undergoing maintenance dialysis show some evidence of muscle wasting. ESKD is associated with an increase in inflammatory cytokines and can result in cachexia, with the loss of muscle and fat stores. At present, only limited data are available on the classification of wasting experienced by persons with ESKD. Individuals with ESKD often exhibit symptoms of anorexia, loss of lean muscle mass and altered energy expenditure. These symptoms are consistent with the syndrome of cachexia observed in other chronic diseases, such as cancer, heart failure, and acquired immune deficiency syndrome. While definitions of cachexia have been developed for some diseases, such as cardiac failure and cancer, no specific cachexia definition has been established for chronic kidney disease. The importance of developing a definition of cachexia in a population with ESKD is underscored by the negative impact that symptoms of cachexia have on quality of life and the association of cachexia with a substantially increased risk of premature mortality. The aim of this study is to determine the clinical phenotype of cachexia specific to individuals with ESKD. METHODS: A longitudinal study which will recruit adult patients with ESKD receiving haemodialysis attending a Regional Nephrology Unit within the United Kingdom. Patients will be followed 2 monthly over 12 months and measurements of weight; lean muscle mass (bioelectrical impedance, mid upper arm muscle circumference and tricep skin fold thickness); muscle strength (hand held dynamometer), fatigue, anorexia and quality of life collected. We will determine if they experience (and to what degree) the known characteristics associated with cachexia. DISCUSSION: Cachexia is a debilitating condition associated with an extremely poor outcome. Definitions of cachexia in chronic illnesses are required to reflect specific nuances associated with each disease. These discrete cachexia definitions help with the precision of research and the subsequent clinical interventions to improve outcomes for patients suffering from cachexia. The absence of a definition for cachexia in an ESKD population makes it particularly difficult to study the incidence of cachexia or potential treatments, as there are no standardised inclusion criteria for patients with ESKD who have cachexia. Outcomes from this study will provide much needed data to inform development and testing of potential treatment modalities, aimed at enhancing current clinical practice, policy and education

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

Carcinoma of unknown primary site remains a common clinical diagnosis, accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0–48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 mg m−2 on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m−2 on day 1) and continuous infusion 5-fluorouracil (300 mg m−2 daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient). Toxicity was acceptable, with 19% grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there were no treatment-related deaths, however, six patients developed thrombotic complications. The overall response rate was 27% (CR 3%; PR 23%). Median time to progression was 3.4 months (95% CI 1.1–5.6 months) and median overall survival was 7.7 months (95% CI 5.7–9.8 months). Survival at 1 year was 28%, and at 2 years, 10%. MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease